MARKET NEWS

Theratechnologies’ Lead Peptide Drug Conjugate TH1902 Receives FDA Fast-Track Designation
Decibel & Catalent Sign Development & Manufacturing Agreement for Dual-Vector Gene Therapy for the Treatment of Congenital Hearing
X-Chem Enters Multitarget Oncology Discovery Research Collaboration & License Agreement With Genentech
Gerresheimer Has Optimized the Test Cartridge & Reagent Block for Ergonomic Handling & Plastic-Suitable Production
Patent on Improved Particle Size Testing Method Granted to Hovione Will Impact Market
GSK & CureVac to Develop Next-Generation mRNA COVID-19 Vaccines
Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia & Cushing’s Disease Advances Into Phase 1 Study
Venthera Doses First Patient With Topical Therapy Targeting Genetic Drivers of Rare Vascular Anomalies

  FEATURED EDITORIAL

 

  COMPANY PROFILE

 

 

Micropore Technologies is a global process technology and service provider to the pharmaceutical industry featuring patented membrane emulsification equipment for the commercially scalable development of microspheres, nanoparticles, and emulsions used in a wide range of controlled release, sterile injectable drug products. Originally spun-out of Loughborough University’s internationally renowned chemical engineering department, the company’s global headquarters and technical center are located in Wilton Center, UK with offices and operations in the USA, India, South Korea & Japan supporting over a hundred clients and strategic partners. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Noble Launches Human Factors Engineering Services to Support Product Development and US FDA Approval of Medical Devices & Combination Products

Noble Launches Human Factors Engineering Services to Support Product Development and US FDA Approval of Medical Devices & Combination Products

Noble, an Aptar Pharma company and world leader in providing drug delivery training device programs for pharmaceutical companies and original equipment manufacturers, recently announced the launch of Human Factors Plus (HF+), an expanded service to further….

Biogen Announces FDA Approval of PLEGRIDY (Peginterferon Beta-1a) Intramuscular Administration for Multiple Sclerosis

Biogen Announces FDA Approval of PLEGRIDY (Peginterferon Beta-1a) Intramuscular Administration for Multiple Sclerosis

Biogen Inc. recently announced the US FDA has approved a new intramuscular (IM) injection route of administration for PLEGRIDY (peginterferon beta-1a) for the treatment of….

Beroni Acquires Majority Interest in Anti-Cancer Drug Development Company

Beroni Acquires Majority Interest in Anti-Cancer Drug Development Company

Beroni Group recently announced it has completed its majority acquisition of the Sydney-based anti-cancer drug development company, PENAO Pty Ltd. As a result of this acquisition….

Albumedix Collaborates With CGT Catapult to Advance Cell & Gene Therapies

Albumedix Collaborates With CGT Catapult to Advance Cell & Gene Therapies

Albumedix Ltd. recently announced it has entered into a collaboration agreement with the Cell and Gene Therapy Catapult (CGT Catapult) to investigate the use of Albumedix´ proprietary albumin-based solutions for….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

February 17 – Formulation Development
February 24 – ODT/Fast Dissolve